Perspective on future peptide and protein-based approaches to therapy of metabolic disease

American Pharmaceutical Review

Volumn 9, Issue 5, 2006, Pages

  Moller, David ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; LEPTIN; MELANOCORTIN 4 RECEPTOR; NEUROPEPTIDE; PEPTIDE; PEPTIDE YY; PROTEIN DERIVATIVE;

BIOTECHNOLOGY; DRUG DELIVERY SYSTEM; GLUCOSE BLOOD LEVEL; HUMAN; HYPOTHALAMUS; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PANDEMIC; PROTEIN ANALYSIS; REVIEW;

EID: 42949128890     PISSN: 10998012     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (17)

1. Krijsa, C., Rogge, M., and Sadee, W. Protein therapeutics: new applications for pharmacogenetics. Nature Reviews 5: 507-521 (2006).
2. Drucker, D. The biology of incretin hormones. Cell Metabolism 3: 153-165 (2006).
3. Pan, C.Q., Buxton, J.M., and Yung, S.L., et al. Design of a long acting peptide functioning as both a glucagon-like peptide-1 receptor agonist and a glucagon receptor antagonist. J. Biol. Chem. 281: 12506-12515 (2006).
4. Fineberg, S.E. Diabetes therapy trials with inhaled insulin. Expert Opin Investig Drugs 15:743-762 (2006).
5. Klonoff, D.C. Technological advances in the treatment of diabetes mellitus: Better bioengineering begets benefits in glucose measurement, the artificial pancreas, and insulin delivery. Pediatr Endocrinol Rev. 1:94-100 (2003).
6. Zhang, B., Moller, D.E. New approaches in the treatment of Type 2 diabetes. 2000 Curr Opinion in Chem Biology 4:461-467.
7. Nawrocki, A.R., and Scherer, P.E. The adipocyte as a drug discovery target. Drug Discovery Today 10, 18: 1219-1230 (2005).
8. Jobst, E.E., Enriori, P.J., and Sinnayah, P., et al. Hypothalamic regulatory pathways and potential obesity treatment targets. Endocrine 29, 1: 33-48 (2006).
9. Hallschmid, M., Benedict, C., and Born, J., et al. Manipulating central nervous mechanisms of food intake and body weight regulation by intranasal administration of neuropeptides in man. Physiology & Behavior 83: 55-64 (2004).
10. Stanley, S., Wynne, K., and Bloom, S. Gastrointestinal satiety signals: Glucagon-like peptide 1, oxyntomodulin, peptide YY, and pancreatic polypeptide. Am J Physiol Gastrointest Liver Physiol 286: G693-G697 (2004).
11. Renshaw, D., and Batterham, R.L. Peptide YY: A potential therapy for obesity. Curr Drug Targets 6: 171-179 (2005).
12. Wynne, K., Park, A.J., and Small, C.J., et al. Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects. Diabetes 54: 2390-2395 (2005).
13. Wortley, K.E., del Rincon, J.P., and Murray, J.D., et al. Absence of ghrelin protects against early-onset obesity. JCI 115, 12: 3573-3578 (2005).
14. Shearman, L.P., Wang, S.P., Helmling, S., et al. Ghrelin neutralization by a ribonucleic acid- SPM ameliorates obesity in diet-induced obese mice. Endocrinol 147, 3: 1517-1526 (2006).
15. Hollander, P., Maggs, D.G., and Ruggles, J.A., et al. Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients. Obes Res 12, 4: 661-8 (2004).
16. Zhang, J.V., Ren, P.G., and Avsian- Kretchmer, O., et al. Obestatin, a peptide encoded by the ghrelin gene, opposes ghrelin's effects on food intake. Science 310: 996-999 (2005).
17. Kharitonenkov, A., Shiyanova, T.L., and Koester, A., et al. FGF-21 as a novel metabolic regulator. J Clin Invest 115: 1627-1635 (2005)